B. Riley Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

B. Riley Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,050	Closed	-$436K	–	1569
2024 Q1	$436K	Buy	+16,050	New	+$473K	0.01%	863
2023 Q4	–	Sell	-16,050	Closed	-$436K	–	1494
2023 Q3	$436K	Sell	16,050 -6,650	-29%	-$198K	0.01%	863
2023 Q2	$698K	Buy	22,700 +9,050	+66%	+$307K	0.02%	711
2023 Q1	$492K	Sell	13,650 -5,500	-29%	-$204K	0.01%	807
2022 Q4	$757K	Sell	19,150 -3,000	-14%	-$125K	0.02%	640
2022 Q3	$890K	Buy	22,150 +8,500	+62%	+$363K	0.03%	541
2022 Q2	$574K	Buy	13,650 +2,100	+18%	+$86.1K	0.02%	602
2022 Q1	$450K	Sell	11,550 -14,330	-55%	-$563K	0.01%	805
2021 Q4	$1.03M	Sell	25,880 -9,400	-27%	-$365K	0.03%	521
2021 Q3	$1.28M	Buy	+35,280	New	+$1.37M	0.04%	448

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

B. Riley Wealth Advisors's RPRX Position: Q2 2024 in Review

B. Riley Wealth Advisors sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 16,050 shares — an estimated $436K sold.

B. Riley Wealth Advisors first reported a position in RPRX in Q3 2021 and held it in 10 quarters. The position peaked at $1.28M in Q3 2021. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

B. Riley Wealth Advisors reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
B. Riley Wealth Advisors sold 16,050 Royalty Pharma shares in Q2 2024, an estimated $436K.
B. Riley Wealth Advisors first reported a position in Royalty Pharma in Q3 2021 and held it in 10 quarters.
B. Riley Wealth Advisors's Royalty Pharma position peaked at $1.28M in Q3 2021.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2024, filed 19 Aug 2024.